Emerging biomarker and genetic studies, including polygenic ADHD risk scores, α-synuclein, amyloid/tau, and GBA mutations, offer opportunities for early detection, risk stratification, and mechanistic insights. This evidence concerns the gene GBA1 and attention deficit-hyperactivity disorder.